Aromatase Inhibitors and Bone Health in Women With Breast Cancer
- 20 November 2006
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (33) , 5305-5312
- https://doi.org/10.1200/jco.2006.07.5382
Abstract
No abstract availableThis publication has 71 references indexed in Scilit:
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoateJournal of Bone and Mineral Research, 1994
- Sex hormones and bone mineral density in elderly menBone and Mineral, 1993
- 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitorJournal of Steroid Biochemistry, 1988
- Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two yearsBreast Cancer Research and Treatment, 1988
- Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosisJournal of Clinical Investigation, 1972